Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/a-novel-property-of-hexokinase-inhibition-by-favipiravir-and-proposed-NVTteJPtEe
References (89)
-
W. Jang, Sangeun Jeon, Seungtaek Kim, Sang Lee (2021)
Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assayProceedings of the National Academy of Sciences of the United States of America, 118
-
Saima Ajaz, M. Mcphail, Keshav Singh, Salma Mujib, F. Trovato, S. Napoli, K. Agarwal (2020)
Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19American Journal of Physiology - Cell Physiology, 320
-
B. Dwarakanath, V. Jain (2009)
Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy.Future oncology, 5 5
-
C. Shang, X. Zhuang, He Zhang, Yiquan Li, Yilong Zhu, Jing Lu, Chenchen Ge, Jianan Cong, Tingyu Li, Mingyao Tian, N. Jin, Xiao Li (2021)
Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic miceVirology Journal, 18
-
(2020)
Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19). A reviewJAMA, 323
-
S. Halder, A. Mehta (2021)
2-Deoxy-D-glucose: is this the final cure for COVID-19: or yet another mirage?European review for medical and pharmacological sciences, 25 13
-
Krystal Fontaine, Erica Sanchez, Roman Camarda, M. Lagunoff (2014)
Dengue Virus Induces and Requires Glycolysis for Optimal ReplicationJournal of Virology, 89
-
Satabdi Saha, Rajat Nandi, Poonam Vishwakarma, Amresh Prakash, Diwakar Kumar (2021)
Discovering Potential RNA Dependent RNA Polymerase Inhibitors as Prospective Drugs Against COVID-19: An in silico ApproachFrontiers in Pharmacology, 12
-
Chang Chen, Yi Zhang, Jianying Huang, P. Yin, Zhenshun Cheng, Jianyuan Wu, Song Chen, Yongxi Zhang, Bo Chen, Mengxin Lu, Yongwen Luo, Lingao Ju, Jingyi Zhang, Xinghuan Wang (2020)
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical TrialmedRxiv
-
U. Agrawal, Reyma Raju, Z. Udwadia (2020)
Favipiravir: A new and emerging antiviral option in COVID-19Medical Journal, Armed Forces India, 76
-
S Padmanabhan (2021)
1Glob J Med Res, 21
-
Katrina Forrestall, D. Burley, M. Cash, I. Pottie, S. Darvesh (2020)
2-Pyridone natural products as inhibitors of SARS-CoV-2 main proteaseChemico-Biological Interactions, 335
-
Qingxian Cai, Minghui Yang, Dongjing Liu, Jun Chen, D. Shu, Junxia Xia, X. Liao, Yu-tong Gu, Q. Cai, Yang Yang, Chenguang Shen, Xiaohe Li, Ling Peng, Deliang Huang, Jing Zhang, Shurong Zhang, Fuxiang Wang, Jiaye Liu, Li Chen, Shuyan Chen, Zhaoqin Wang, Zheng Zhang, Ruiyuan Cao, Wu Zhong, Yingxia Liu, Lei Liu (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control StudyEngineering (Beijing, China), 6
-
S. Paul, Goutam Biswas (2020)
Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.Mini reviews in medicinal chemistry
-
P. Icard, H. Lincet, Zherui Wu, A. Coquerel, P. Forgez, M. Alifano, L. Fournel (2020)
The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory responseBiochimie, 180
-
O. Zhirnov, Alyona Chernyshova (2021)
Favipiravir: the hidden threat of mutagenic actionJournal of microbiology, epidemiology and immunobiology, 98
-
Jiaofeng Huang, Aiguo Cheng, Rahul Kumar, Yingying Fang, Gongping Chen, Yueyong Zhu, Su Lin (2020)
Hypoalbuminemia predicts the outcome of COVID‐19 independent of age and co‐morbidityJournal of Medical Virology, 92
-
K. Sahu, Raman Kumar (2021)
Role of 2-Deoxy-D-Glucose (2-DG) in COVID-19 disease: A potential game-changerJournal of Family Medicine and Primary Care, 10
-
J. Malin, I. Suárez, Vanessa Priesner, G. Fätkenheuer, J. Rybniker (2020)
Remdesivir against COVID-19 and Other Viral DiseasesClinical Microbiology Reviews, 34
-
(Tempestilli M, Caputi P, Avataneo V et al (2020) Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother 75:2977–2980)
Tempestilli M, Caputi P, Avataneo V et al (2020) Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother 75:2977–2980Tempestilli M, Caputi P, Avataneo V et al (2020) Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother 75:2977–2980, Tempestilli M, Caputi P, Avataneo V et al (2020) Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother 75:2977–2980
-
Oraphan Phuangsawai, S. Hannongbua, M. Gleeson (2014)
Elucidating the origin of the esterase activity of human serum albumin using QM/MM calculations.The journal of physical chemistry. B, 118 41
-
P. Prajapati, Heli Desai, Chandni Chandarana (2022)
Hand sanitizers as a preventive measure in COVID-19 pandemic, its characteristics, and harmful effects: a reviewJournal of the Egyptian Public Health Association, 97
-
Kent Doi, Mahoko Ikeda, Naoki Hayase, K. Moriya, N. Morimura, Hiromu Tak, Hiromu Maehara, S. Tagami, Kazutaka Fukushima, Naho Misawa, Yutaro Inoue, H. Nakamura, D. Takai, Mio Kurimoto, Kurato Tokunaga, Miyuki Yamamoto, Ichiro Hirayama, Ryohei Horie, Yurina Endo, Kengo Hiwatashi, Mio Shikama, Daisuke Jubishi, Yoshiaki Kanno, K. Okamoto, Sohei Harada, S. Okugawa, K. Miyazono, Y. Seto, Jun-ichiro Inoue (2020)
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case seriesCritical Care, 24
-
Y. Furuta, B. Gowen, Kazumi Takahashi, K. Shiraki, D. Smee, D. Barnard (2013)
Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral research, 100 2
-
Jian-yuan Zhao, Saisai Guo, Dongrong Yi, Quanjie Li, Ling Ma, Yong-xin Zhang, Jing Wang, Xiaoyu Li, Fei Guo, R. Lin, C. Liang, Zhenlong Liu, S. Cen (2021)
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymeraseAntiviral Research, 190
-
I. Darazam, S. Shokouhi, M. Pourhoseingholi, Seyed Irvani, M. Mokhtari, M. Shabani, Mahdi Amirdosara, Parham Torabinavid, M. Golmohammadi, S. Hashemi, Arsalan Azimi, Mohammad Maivan, Omidvar Rezaei, A. Zali, M. Hajiesmaeili, Hadiseh Dehbsneh, Akram Kusha, Maryam Shoushtari, N. Khalili, Azam Soleymaninia, L. Gachkar, A. Khoshkar (2021)
Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trialScientific Reports, 11
-
(Su H-X, Yao S, Zhao, W-F et al (2020) Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 1–11)
Su H-X, Yao S, Zhao, W-F et al (2020) Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 1–11Su H-X, Yao S, Zhao, W-F et al (2020) Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 1–11, Su H-X, Yao S, Zhao, W-F et al (2020) Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 1–11
-
M. Imran, Mandeep Arora, S. Asdaq, Shahalam Khan, Saleh Alaqel, M. Alshammari, M. Alshehri, A. Alshrari, Alreshidi Ali, A. Al-Shammeri, B. Alhazmi, Aisha Harshan, Md. Alam, Abida Abida (2021)
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19Molecules, 26
-
Ahmed Al-Ziaydi, Ahmed Al-Shammari, M. Hamzah, H. Kadhim, M. Jabir (2020)
Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cellsCancer Cell International, 20
-
H. Su, Sheng Yao, Wen Zhao, Minjun Li, Jia Liu, W. Shang, Hang Xie, Chang-qiang Ke, Hang-chen Hu, Mei-na Gao, Kunqian Yu, Hong Liu, Jingshan Shen, Wei Tang, Lei-ke Zhang, Geng-Fu Xiao, Li Ni, Daowen Wang, Jian-Ping Zuo, Hualiang Jiang, Fang Bai, Yan Wu, Y. Ye, Ye-chun Xu (2020)
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredientsActa Pharmacologica Sinica, 41
-
R. Abdelnabi, C. Foo, S. Kaptein, Xin Zhang, Thuc Do, Lana Langendries, L. Vangeel, J. Breuer, J. Pang, Rachel Williams, V. Vergote, E. Heylen, P. Leyssen, K. Dallmeier, Lotte Coelmont, A. Chatterjee, R. Mols, P. Augustijns, S. Jonghe, D. Jochmans, B. Weynand, J. Neyts (2021)
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection modelEBioMedicine, 72
-
Ye-ming Wang, Dingyu Zhang, G. Du, R. Du, Jianping Zhao, Yang Jin, Shouzhi Fu, Ling Gao, Zhenshun Cheng, Q. Lu, Y. Hu, G. Luo, Ke Wang, Yang Lu, Huadong Li, Shuzhen Wang, Shunan Ruan, Chengqing Yang, Chunlin Mei, Yi Wang, Dan Ding, Feng Wu, Xin Tang, X. Ye, Yingchun Ye, Bing Liu, Jie Yang, Wen Yin, Aili Wang, Guohui Fan, F. Zhou, Zhibo Liu, Xiaoying Gu, Jiuyang Xu, L. Shang, Yi Zhang, Lianjun Cao, Tingting Guo, Y. Wan, H. Qin, Yushen Jiang, T. Jaki, F. Hayden, P. Horby, B. Cao, Chen Wang (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialLancet (London, England), 395
-
Combi - nation of QSAR , molecular docking , molecular dynamic simulation and MM - PBSA : analogues of lopinavir and favipiravir as potential drug candidates against COVID - 19 -
E. Takashita, N. Kinoshita, S. Yamayoshi, Yuko Sakai-Tagawa, Seiichiro Fujisaki, Mutsumi Ito, K. Iwatsuki-Horimoto, S. Chiba, P. Halfmann, H. Nagai, M. Saito, E. Adachi, D. Sullivan, A. Pekosz, Shinji Watanabe, K. Maeda, M. Imai, H. Yotsuyanagi, H. Mitsuya, N. Ohmagari, M. Takeda, H. Hasegawa, Y. Kawaoka (2022)
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron VariantThe New England Journal of Medicine
-
MK Mantha (2021)
347Biomed Biotechnol Res J, 5
-
Maria Nicola, Z. Alsafi, C. Sohrabi, Ahmed Kerwan, A. Al-Jabir, Christos Iosifidis, M. Agha, R. Agha (2020)
The socio-economic implications of the coronavirus pandemic (COVID-19): A reviewInternational Journal of Surgery (London, England), 78
-
Yuli Qian, J. Markowitz (2020)
Natural Products as Modulators of CES1 ActivityDrug Metabolism and Disposition, 48
-
L. Sanders, A. Fortin, G. Schiff (2020)
Connecting With Patients-The Missing Links.JAMA, 323 1
-
Ji-Hyun Kang, Young-Jin Kim, Min-Seok Yang, D. Shin, Dong-Wook Kim, I. Park, Chun-Woong Park (2021)
Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in RatsPharmaceutics, 13
-
Jin-Yan Li, Zhi You, Qiong Wang, Z. Zhou, Ye Qiu, Rui Luo, Xingyi Ge (2020)
The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the futureMicrobes and Infection, 22
-
G. Painter, R. Bowen, Gregory Bluemling, John DeBergh, Vindhya Edpuganti, Prabhakar Gruddanti, D. Guthrie, Michael Hager, D. Kuiper, M. Lockwood, Deborah Mitchell, M. Natchus, Zachary Sticher, A. Kolykhalov (2019)
The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection.Antiviral research
-
Md. Rafi, Khattab Al-Khafaji, T. Tok, Md. Rahman (2020)
Computer-based identification of potential compounds from Salviae miltiorrhizae against Neirisaral adhesion A regulatory proteinJournal of Biomolecular Structure and Dynamics, 40
-
M. Tempestilli, Priscilla Caputi, V. Avataneo, S. Notari, Olindo Forini, L. Scorzolini, L. Marchioni, Tommaso Bartoli, C. Castilletti, E. Lalle, M. Capobianchi, E. Nicastri, A. D’Avolio, Giuseppe Ippolito, C. Agrati, Maria Abbonizio, C. Agrati, F. Albarello, G. Amadei, A. Amendola, A. Antinori, M. Antonini, R. Barbaro, B. Bartolini, M. Benigni, N. Bevilacqua, L. Bordi, V. Bordoni, Marta Branca, P. Campioni, M. Capobianchi, C. Caporale, Ilaria Caravella, F. Carletti, R. Casetti, C. Castilletti, R. Chiappini, C. Ciaralli, E. Cimini, F. Colavita, A. Corpolongo, M. Cristofaro, Salvatore Curiale, A. D'Abramo, C. Dantimi, A. Angelis, Giada Angelis, Rachele Lorenzo, F. Stefano, G. D’Offizi, F. Ferraro, Lorena Fiorentini, A. Frustaci, P. Gallì, G. Garotto, M. Giancola, Filippo Giansante, E. Giombini, G. Grassi, Maria Greci, Giuseppe Ippolito, E. Lalle, S. Lanini, D. Lapa, L. Lepore, Andrea Lúcia, Franco Lufrani, Manuela Macchione, A. Marani, L. Marchioni, A. Mariano, M. Marini, M. Maritti, G. Matusali, S. Meschi, F. Messina, C. Montaldo, S. Murachelli, E. Nicastri, R. Noto, C. Palazzolo, Emanuele Pallini, F. Palmieri, V. Passeri, Federico Pelliccioni, A. Petrecchia, Ada Petrone, N. Petrosillo, E. Pianura, M. Pisciotta, S. Pittalis, Costanza Proietti, V. Puro, Gabriele Rinonapoli, Martina Rueca, A. Sacchi, Francesco Sanasi, C. Santagata, S. Scarcia, V. Schininà, P. Scognamiglio, L. Scorzolini, G. Stazi, F. Vaia, F. Vairo, M. Valli (2020)
Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19Journal of Antimicrobial Chemotherapy
-
(2020)
Molecular docking studies of some antiviral and antimalarial drugs via bindings to 3CL-protease and polymerase enzymes of the novel coronavirus (SARSCoV-2) -
SB Palghadmal (2021)
193Explor Res Hypothesis Med, 6
-
Minchen Chien, T. Anderson, S. Jockusch, C. Tao, Xiaoxu Li, Shiv Kumar, J. Russo, R. Kirchdoerfer, J. Ju (2020)
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19Journal of Proteome Research, 19
-
Victoria Yan, F. Muller (2020)
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 TreatmentACS Medicinal Chemistry Letters, 11
-
A. Eweas, Amr Alhossary, A. Abdel-Moneim (2021)
Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2Frontiers in Microbiology, 11
-
I. Madabhavi, Md Sarkar, Nagaveni Kadakol (2020)
COVID-19: a review.Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 90 2
-
A. Bhatt, Abhishek Kumar, Y. Rai, Neeraj Kumari, Dhiviya Vedagiri, K. Harshan, Vijayakumar Chinnadurai, S. Chandna (2021)
Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virionsLife Sciences, 295
-
Sanchit Seth, J. Batra, Srilakshmi Srinivasan (2020)
COVID-19: Targeting Proteases in Viral Invasion and Host Immune ResponseFrontiers in Molecular Biosciences, 7
-
K. Wanat (2020)
Biological barriers, and the influence of protein binding on the passage of drugs across themMolecular Biology Reports, 47
-
P. Reading, J. Allison, E. Crouch, E. Anders (1998)
Increased Susceptibility of Diabetic Mice to Influenza Virus Infection: Compromise of Collectin-Mediated Host Defense of the Lung by Glucose?Journal of Virology, 72
-
A. Wahl, Lisa Gralinski, Claire Johnson, Wenbo Yao, M. Kovárová, K. Dinnon, Hongwei Liu, V. Madden, Halina Krzystek, C. De, Kristen White, K. Gully, A. Schäfer, Tanzila Zaman, S. Leist, P. Grant, Gregory Bluemling, A. Kolykhalov, M. Natchus, F. Askin, G. Painter, E. Browne, Corbin Jones, R. Pickles, R. Baric, J. Garcia (2021)
SARS-CoV-2 Infection is Effectively Treated and Prevented by EIDD-2801Nature, 591
-
L. Courteau, J. Crasto, G. Hassanzadeh, S. Baird, J. Hodgins, U. Liwak-Muir, G. Fung, H. Luo, D. Stojdl, R. Screaton, M. Holcik (2015)
Hexokinase 2 controls cellular stress response through localization of an RNA-binding proteinCell Death & Disease, 6
-
A. Ivashchenko, K. Dmitriev, N. Vostokova, V. Azarova, A. Blinow, A. Egorova, I. Gordeev, A. Ilin, R. Karapetian, D. Kravchenko, N. Lomakin, E. Merkulova, N. Papazova, E. Pavlikova, N. Savchuk, E. Simakina, T. Sitdekov, E. Smolyarchuk, E. Tikhomolova, E. Yakubova, A. Ivachtchenko (2020)
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical TrialClinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 73
-
Y. Furuta, T. Komeno, Takaaki Nakamura (2017)
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymeraseProceedings of the Japan Academy. Series B, Physical and Biological Sciences, 93
-
Tao Shen, Tingting Wang (2021)
Metabolic Reprogramming in COVID-19International Journal of Molecular Sciences, 22
-
Yan Ng, Cyrill Salim, J. Chu (2021)
Drug repurposing for COVID-19: Approaches, challenges and promising candidatesPharmacology & Therapeutics, 228
-
C. Scholtissek, R. Rott, G. Hau, G. Kaluza (1974)
Inhibition of the Multiplication of Vesicular Stomatitis and Newcastle Disease Virus by 2-Deoxy-d-GlucoseJournal of Virology, 13
-
S. Padmanabhan (2021)
Potassium Levels in COVID Subjects: Current Observations and New Possibilities for its use in COVID Diagnosis -
B. Malone, E. Campbell (2021)
Molnupiravir: coding for catastropheNature Structural & Molecular Biology, 28
-
H. Mengist, T. Dilnessa, T. Jin (2021)
Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main ProteaseFrontiers in Chemistry, 9
-
Shahalam Khan, K. Al-Balushi (2020)
Combating COVID-19: The role of drug repurposing and medicinal plantsJournal of Infection and Public Health, 14
-
F. Bahar, Kayoko Ohura, T. Ogihara, T. Imai (2012)
Species difference of esterase expression and hydrolase activity in plasma.Journal of pharmaceutical sciences, 101 10
-
K. Teralı, B. Baddal, H. Gülcan (2020)
Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experimentJournal of Molecular Graphics & Modelling, 100
-
Yining Wang, Pengfei Li, Kundan Solanki, Yang Li, Zhongren Ma, M. Peppelenbosch, M. Baig, Q. Pan (2021)
Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronavirusesVirology, 564
-
Yuemao Shen, William Eades, B. Yan (2021)
The COVID‐19 Medicine Remdesivir Is Therapeutically Activated by Carboxylesterase‐1, and Excessive Hydrolysis Increases CytotoxicityHepatology Communications, 5
-
Tadele Girum, Kifle Lentiro, Mulugeta Geremew, Biru Migora, S. Shewamare (2020)
Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic reviewTropical Medicine and Health, 48
-
P. Venkatesan (2021)
Repurposing drugs for treatment of COVID-19The Lancet. Respiratory Medicine, 9
-
M. Kheir, F. Saleem, Christy Wang, Amardeep Mann, Jimmy Chua (2021)
Higher albumin levels on admission predict better prognosis in patients with confirmed COVID-19PLoS ONE, 16
-
A. Ivashchenko, K. Dmitriev, N. Vostokova, V. Azarova, A. Blinow, A. Egorova, I. Gordeev, A. Ilin, R. Karapetian, D. Kravchenko, N. Lomakin, E. Merkulova, N. Papazova, E. Pavlikova, N. Savchuk, E. Simakina, T. Sitdekov, E. Smolyarchuk, E. Tikhomolova, E. Yakubova, A. Ivachtchenko (2020)
AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical TrialmedRxiv
-
S Halder (2021)
4448Eur Rev Med Pharmacol Sci, 25
-
Z. Merali, S. Ross, G. Paré (2014)
The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effectDrug Metabolism and Drug Interactions, 29
-
F. Rinkevich, J. Margotta, M. Simone-Finstrom, L. Guzman, K. Healy (2018)
Esterase Activity is Affected by Genetics, Age, Insecticide Exposure, and Viral Infection in the Honey Bee, Apis melliferabioRxiv
-
K. Abuga, N. Nyamweya (2021)
Alcohol-Based Hand Sanitizers in COVID-19 Prevention: A Multidimensional PerspectivePharmacy: Journal of Pharmacy Education and Practice, 9
-
Chang Chen, Yi Zhang, Jianying Huang, P. Yin, Zhenshun Cheng, Jianyuan Wu, Song Chen, Yongxi Zhang, Bo Chen, Mengxin Lu, Yongwen Luo, Lingao Ju, Jingyi Zhang, Xinghuan Wang (2021)
Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical TrialFrontiers in Pharmacology, 12
-
JJ Malin (2021)
e00162Clin Microbiol Rev, 34
-
Yunfeng Shang, Haiwei Li, Ren Zhang (2021)
Effects of Pandemic Outbreak on Economies: Evidence From Business History ContextFrontiers in Public Health, 9
-
Mani Mantha, Tarun Suvvari, A. Corriero (2021)
2-Deoxy-D-glucose as an armament against COVID-19: The key to return to normality?Biomedical and Biotechnology Research Journal (BBRJ), 5
-
A. Rabie (2021)
RETRACTED ARTICLE: Discovery of (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drugChemicke Zvesti, 75
-
(Rinkevich FD, Margotta JW, Simone-Finstrom M et al (2018) Esterase activity is affected by genetics, age, insecticide exposure, and viral infection in the honey bee, Apis mellifera. Biorxiv)
Rinkevich FD, Margotta JW, Simone-Finstrom M et al (2018) Esterase activity is affected by genetics, age, insecticide exposure, and viral infection in the honey bee, Apis mellifera. BiorxivRinkevich FD, Margotta JW, Simone-Finstrom M et al (2018) Esterase activity is affected by genetics, age, insecticide exposure, and viral infection in the honey bee, Apis mellifera. Biorxiv, Rinkevich FD, Margotta JW, Simone-Finstrom M et al (2018) Esterase activity is affected by genetics, age, insecticide exposure, and viral infection in the honey bee, Apis mellifera. Biorxiv
-
T. Sagawa, Ken-ichiro Inoue, H. Takano (2020)
Use of protease inhibitors for the prevention of COVID-19Preventive Medicine, 141
-
S. Palghadmal, P. Kulkarni, Vishal Makadia, Mahesh Deshmukh, Priyanka Gondhale, S. Padmanabhan (2021)
Tackling Complications of Coronavirus Infection with Quercetin: Observations and HypothesesExploratory Research and Hypothesis in Medicine
-
L. Vangeel, Winston Chiu, S. Jonghe, P. Maes, Bram Slechten, J. Raymenants, E. André, P. Leyssen, J. Neyts, D. Jochmans (2021)
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concernAntiviral Research, 198
-
C. Ramière, J. Rodriguez, L. Enache, V. Lotteau, P. André, Olivier Diaz (2014)
Activity of Hexokinase Is Increased by Its Interaction with Hepatitis C Virus Protein NS5AJournal of Virology, 88
-
Tatu Pantsar, A. Poso (2018)
Binding Affinity via Docking: Fact and FictionMolecules : A Journal of Synthetic Chemistry and Natural Product Chemistry, 23
-
W. Painter, W. Holman, J. Bush, F. Almazedi, H. Malik, N. Eraut, M. Morin, L. Szewczyk, G. Painter (2021)
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2Antimicrobial Agents and Chemotherapy, 65
-
Huan Gao, Di Liang, Chenchen Li, Guoxing Xu, Meng-Nan Jiang, Heng Li, Jianyuan Yin, Yanqing Song (2020)
2-Deoxy-Rh2: A novel ginsenoside derivative, as dual-targeting anti-cancer agent via regulating apoptosis and glycolysis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 124
- Publisher
- Springer Journals
- Copyright
- Copyright © The Author(s), under exclusive licence to Springer Nature B.V. 2022
- ISSN
- 0141-5492
- eISSN
- 1573-6776
- DOI
- 10.1007/s10529-022-03259-6
- Publisher site
- See Article on Publisher Site
Abstract
PurposeIn the wake of SARS-CoV-2’s global spread, human activities from health to social life to education have been affected. Favipiravir and Molnupiravir exhibited novel hexokinase inhibition and we discuss advantages of this property in their COVID-19 inhibition potential.MethodsThis paper describes molecular docking data of human hexokinase II with Favipiravir, Cyan 20, Remdesivir, 2DG, and Molnupiravir along with hexokinase inhibition assays.ResultsFavipiravir, an antiviral drug previously cleared for treating the flu and ebola, has shown some promise in early trials to treat COVID-19. We observed potent human hexokinase inhibiting potential of Favipiravir (50%) as against 4% and merely 0.3% hexokinase inhibition with Molnupiravir and 2 Deoxy d glucose at 0.1 mM concentration supported by molecular docking studies.ConclusionFavipiravir could continue to be part of the COVID-19 treatment regimen due to its resistance to host esterases, hexokinase inhibition potential and proven safety through human trials.
Journal
Biotechnology Letters – Springer Journals
Published: Jul 1, 2022
Keywords: Favipiravir; Molnupiravir; 2 Deoxy d glucose; Hexokinase; Molecular docking; COVID-19